US · RNA
Atrium Therapeutics, Inc.
- Sector
- Healthcare · Biotechnology
- Headquarters
- San Diego, CA 92121
- Website
- atriumtherapeutics.com
Price · as of 2026-07-06
$13.01
Market cap 228.36M
Price history
Valuation history
Annual price overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | |||||
| 2018 | |||||
| 2019 | $0.00 | $0.00 | |||
| 2020 | $3.90 | $0.00 | |||
| 2021 | $0.00 | $0.00 | |||
| 2022 | $0.00 | $0.00 | |||
| 2023 | $0.00 | $0.00 | |||
| 2024 | $0.00 | $0.00 | |||
| 2025 | $14.91 | $21.71 | $6.29 |
Line items
Line items
Line items
About Atrium Therapeutics, Inc.
Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies. The company's development stage product candidates include ATR 1072, a siRNA-based therapy targeting PRKAG2 for the treatment of PRKAG2 syndrome; and ATR 1086, a siRNA-based therapy targeting PLN for the treatment of PLN cardiomyopathy. It also focuses on pipeline to treat a range of genetic and cardiac diseases. The company was incorporated in 2025 and is headquartered in San Diego, California.
- CEO
- Kathleen Gallagher
- Employees
- 511
- Beta
- 0.00
Peer comparison
Same-industry comparables, ranked by market cap.
Scroll horizontally for additional metrics. Ticker column stays fixed.
| Basic Info | Model Valuation | Core Valuation | Growth | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | Sales Growth |
| RNA | Atrium Therapeutics, Inc. | $13.65 | 228.36M | +59% | -29% | — | — | -3.00 | 1.22 | 109.48 | -0.66 | 7211.00% |
| ABVX | Abivax S.A. | $121.28 | 7.95B | -67% | -97% | — | — | -2.42 | 10.50 | 39.48 | -2.21 | 13354.00% |
| CAI | Caris Life Sciences, Inc. | $20.14 | 5.68B | +132% | +1,824% | — | — | -507.35 | 59.84 | 42.54 | 2965.27 | 9697.00% |
| CYTK | Cytokinetics, Incorporate… | $62.22 | 7.61B | -4% | -58% | — | — | -9.39 | -11.18 | 83.75 | -10.03 | 37656.00% |
| JAZZ | Jazz Pharmaceuticals plc | $190.02 | 11.7B | -5% | +4% | -94% | — | -32.61 | 2.69 | 2.72 | 104.22 | 488.00% |
| MDGL | Madrigal Pharmaceuticals,… | $432.00 | 9.81B | -42% | +134,896% | — | — | -33.90 | 16.22 | 10.20 | -34.57 | 43205.00% |
| MRNA | Moderna, Inc. | $53.57 | 20.93B | -39% | -61% | — | +298% | -7.28 | 2.38 | 10.57 | -6.53 | -3923.00% |
| MRUS | Merus N.V. | $90.00 | 6.83B | -61% | -76% | — | -87% | -13.74 | 4.57 | 84.83 | -9.34 | -1238.00% |
| NUVL | Nuvalent, Inc. | $101.95 | 7.41B | — | — | — | — | -17.31 | 5.90 | — | -571.33 | — |
| RYTM | Rhythm Pharmaceuticals, I… | $92.73 | 6.19B | -37% | +4,762% | — | — | -31.39 | 44.36 | 32.51 | -33.22 | 4583.00% |
| TECH | Bio-Techne Corporation | $59.00 | 9.23B | -19% | -63% | -94% | -90% | 116.45 | 4.45 | 7.01 | 40.71 | 523.00% |
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($9.65 ÷ $13.01) − 1 = -25.83% (DCF, example).